Repaglinide-loaded solid lipid nanoparticles: Effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Ebrahimi, Hossein Ali ^a,b,c   Javadzadeh, Yousef ^a,b   Hamidi, Mehrdad ^c,d   Jalali, Mohammad Barzegar ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXCIPIENT; GLYCEROL STEARATE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; POLYVINYL ALCOHOL; POVIDONE; REPAGLINIDE; SOLID LIPID NANOPARTICLE; STABILIZING AGENT; STEARIC ACID; SURFACTANT; CARBAMIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION; NANOPARTICLE; PIPERIDINE DERIVATIVE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INFRARED SPECTROSCOPY; KINETICS; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG STABILITY;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMATES; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; HYPOGLYCEMIC AGENTS; NANOPARTICLES; PARTICLE SIZE; PIPERIDINES; SURFACE-ACTIVE AGENTS;

EID: 84942049592     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-015-0128-3     Document Type: Article

References (36)

1. Yao J, Shi YQ, Li ZR, Jin SH. Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs. J Chromatogr B. 2007;853:254-9.
2. Culy JR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61:1625-60.
3. El-Houssieny BM, Wahman L, Arafa NM. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. BioScience Trends. 2010;4(1):17-24.
4. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization. J Control Release. 2005;107:300-9.
5. Lokhande AB, Mishra S, Kulkarni RD, Naik JB. Preparation and characterization of repaglinide loaded ethylcellulose nanoparticles by solvent diffusion technique using high pressure homogenizer. J Pharm Res. 2013;7:421-6.
6. UM D l, Poovi G, Neelakanta Reddy P. In vitro characterization and in vivo toxicity studyofrepaglinideloadedpoly (methyl methacrylate)nanoparticles. Int J Pharm. 2010;396:194-203.
7. Demirel M, Yazan Y, Müller RH, Kiliç F, Bozan B. Formulation and in vitro-in vivo evaluation of piribidil solid lipid micro and nanoparticles. J Microencapsul. 2001;18(3):359-71.
8. Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci. 2009;334:75-81.
9. Radomska-Soukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59:411-8.
10. Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure. Int J Pharm. 2011;406:163-72.
11. Xie S, Wang S, Zhu L, Wang F, Zhou W. The effect of glycolic acid monomer ratio on the emulsifying activity of PLGA in preparation of protein-loaded SLN. Colloids and Surfaces B. Biointerfaces. 2009;74:358-61.
12. Tan SW, Billa N, Roberts CR, Burley JC. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids and Surfaces A: Physicochem. Eng Aspects. 2010;372:73-9.
13. Salminen H, Aulbach S, Leuenberger BH, Tedeschi C. Influence of surfactant composition on physical and oxidative stability of Quillaja saponin-stabilized lipid particles with encapsulated omega-3 fish oil. Colloids and Surfaces B. Biointerfaces. 2014;122:46-55.
14. Keck CM, Kovačević A, Müller RH, Savić S, Vuleta G, Milić J. Formulation of solid lipid nanoparticles (SLN): The value of different alkyl polyglucoside surfactants. Int J Pharm. 2014;474:33-41.
15. Olbrich C, Müller RH. Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures. Int J Pharm. 1999;180:31-9.
16. Wolfgang Mehnert KM. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-96.
17. Schöler N, Olbrich C, Tabatt K, Müller RH, Hahn H, Liesenfeld O. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm. 2001;221:57-67.
18. Schubert MA, Müller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm. 2005;61:77-86.
19. Fei H, Sanming L, Ran Y, Hongzhuo L, Lu X. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids and surfaces a. A Physicochem Eng Asp. 2008;315:210-6.
20. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm. 2003;257:153-60.
21. Paulo Costa JMSL. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-33.
22. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release. 1993;25(1-2):89-98.
23. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56:1527-35.
24. Melike Üner GY. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
25. Luo F, Chen DW, Ren LX, Zhao XL, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114:53-9.
26. Rawat MK, Jain A, Mishra A, Muthu MS, Singh S. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. Curr Drug Deliv. 2010;7:44-50.
27. Mulla JAS, Hiremath SP, Sharma NK. Repaglinide loaded solid lipid nanoparticles: design and characterization. RGUHS J Pharm Sci. 2012;2(4):41-9.
28. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50.
29. Gardouh AR, Gad S, Ghonaim HM, Ghorab MM. Design and characterization of glyceryl monostearate solid lipid nanoparticles prepared by high shear homogenization. British J Pharmaceutical Res. 2013;3(3):326-46.
30. Kavitha R, Sathali AA. Enhancement of solubility of repaglinide by solid dispersion technique. Int J Chem Sci. 2012;10(1):377-90.
31. Almeida EDP, Costa AA, Serafini MR, Rossetti FC, Marchetti JM, Sarmento VHV, et al. Preparation and characterization of chloroaluminum phthalocyanine-loaded solid lipid nanoparticles by thermal analysis and powder X-ray diffraction techniques. J Therm Anal Calorim. 2011;108:191-6.
32. Pelczarska A, Delie F, Domańska U, Carrupt PA, Martel S. New high throughput screening method for drug release measurements. Eur J Pharm Biopharm. 2013;85:151-7.
33. Barzegar-Jalali M, Adibkia K, Valizadeh H, Siahi Shadabad MR, Nokhodchi A, Omidi Y, et al. Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci. 2008;11(1):167-77.
34. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci. 1969;58(10):1253-7.
35. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008;364:328-43.
36. Siepmanna J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48:139-57.